scout
|Articles|November 16, 2009

Oncology NEWS International

  • Oncology NEWS International Vol 18 No 11
  • Volume 18
  • Issue 11

Astellas, Medivation team on prostate Rx

Astellas has partnered with Medivation to co-develop and market the oral anti-androgen, MDV3100. In September, Medivation enrolled patients in the phase III AFFIRM trial, which is evaluating MDV3100 in 1,200 men with castration-resistant prostate cancer who were previously treated with docetaxel (Doxil) chemotherapy.

Astellas has partnered with Medivation to co-develop and market the oral anti-androgen, MDV3100. In September, Medivation enrolled patients in the phase III AFFIRM trial, which is evaluating MDV3100 in 1,200 men with castration-resistant prostate cancer who were previously treated with docetaxel (Doxil) chemotherapy.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.


Latest CME